Michael Jain

56PUBLICATIONS
331CO-AUTHORS
Predictive and prognostic markersHaematological tumoursMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (56)

|Oct 07, 2026
Clinical Features and Outcomes of Therapy-Related Myeloid Neoplasms After CAR T-Cell Therapy.

|Sep 30, 2026
IFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma.

|Sep 18, 2026
RHOA Deletion Downregulates CD19 and Promotes Dysfunctional Immune Microenvironments in CAR-T Resistant Large B-cell Lymphomas.

|Jul 21, 2026
Chronic graft-versus-host disease after PTCy-based prophylaxis vs non-PTCy prophylaxis.

|Jul 17, 2026
A novel severe toxicity-free, and progression-free survival endpoint predicts outcomes after CD19 chimeric antigen receptor-T cell therapy in large B-cell lymphoma.

|Jul 08, 2026
Identification of an optimal absolute lymphocyte count at leukapheresis in patients with lymphoma treated with CART.

Pageof 10

Frequent Collaborators

18 joint publications

Frederick Locke

16 joint publications

Marco L Davila

12 joint publications

Taiga Nishihori

12 joint publications

Marion Subklewe